Therapeutic effect of oral NAC on Sinusitis

Evaluation of therapeutic effect of oral N-Acetyl Cystein in comparison with placebo in patients diagnosed as subacute sinusitis, a double blind placebo controlled randomized clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT138806112406N1

Enrollment

Registered

2010-01-27

Start date

2008-11-19

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

subacute Sinusitis.

Interventions

Intervention 1: Co-Amoxiclav (Amoxicillin 500 mg and Clavulanic acid 125mg Q8h, orally), pseudoephedrine (60mg three times a day, orally), and Sodium chloride irrigation plus N-Acetyl Cysteine (6oo mg

Treatment - Drugs

Co-Amoxiclav (Amoxicillin 500 mg and Clavulanic acid 125mg Q8h, orally), pseudoephedrine (60mg three times a day, orally), and Sodium chloride irrigation plus N-Acetyl Cysteine (6oo mg, three times a

Co-Amoxiclav (Amoxicillin 500 mg and Clavulanic acid 125mg Q8h, orally), pseudoephedrine (60mg three times a day, orally), and Sodium chloride irrigation plus placebo.

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Presence of subacute sinusitis according to signs and symptoms 3 weeks to 3 months and signs of sinusitis in CT scan Exclusion criteria: Presence of allergic rhinitis, asthma, pregnancy, diabetes mellitus, transplantation, CRF, chronic alcoholism, severe malnutrition, AIDS, Down syndrome, history of migraine, HTN, BPH, consumption of antidepressants, Methyl dopa, Propranolol, or Warfarin, history of kidney stone, or liver disease, more than 60 years old age, drivers, or pilots

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Culture of nasal secretion. Timepoint: 1 month after competement of treatment. Method of measurement: microbiological culture.;Signs and symptoms of disease. Timepoint: 1 day after completement of treatment. Method of measurement: face to face completement of Snot 20 questionnaire by a physician.;Involvement of paranasal sinuses. Timepoint: 1 month after competement of treatment. Method of measurement: CT scan, cure rate of sinusitis according to Lund-Mackay score.	—

Measure

Time frame

Culture of nasal secretion. Timepoint: 1 month after competement of treatment. Method of measurement: microbiological culture.;Signs and symptoms of disease. Timepoint: 1 day after completement of treatment. Method of measurement: face to face completement of Snot 20 questionnaire by a physician.;Involvement of paranasal sinuses. Timepoint: 1 month after competement of treatment. Method of measurement: CT scan, cure rate of sinusitis according to Lund-Mackay score.

—

Secondary

Measure	Time frame
Clinical improvement. Timepoint: 1 day and one month after copletement of treatment. Method of measurement: snot20 questionaire.;Radiological improvement in paranasal CT scan. Timepoint: 1 month after completment of treatment. Method of measurement: Lund-Mackey score.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Gholam_Hosein Monavvar_Sadegh

Bushehr University of Medical Sciences

dr.monavarsadegh@yahoo.com+98 77 1252 4044

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026